Key result
RNA aptamer ADR58 binds Oncostatin M with ~7 nM affinity to antagonize gp130 signaling in vitro.
Why the study?
Oncostatin M is a proinflammatory cytokine implicated in rheumatoid arthritis and represents a potential novel therapeutic target.
The generated RNA aptamer ADR58 binds specifically to human Oncostatin M with high affinity and antagonizes its signaling, offering a potential tool or therapeutic agent for inflammatory disorders like rheumatoid arthritis.
ADR58 may aid Oncostatin M pathway studies in models; leaves open therapeutic translation in cardiovascular disease.
Oncostatin M (OSM) is a multifunctional member of the interleukin-6 cytokine family. OSM has been implicated as a powerful proinflammatory mediator and may represent a potentially important, novel therapeutic opportunity for treatment of established rheumatoid arthritis. To further investigate the role of OSM in inflammatory disorders, we have isolated a series of RNA aptamers that bind specifically to human OSM. The highest affinity aptamer, designated ADR58, has been characterized in a series of in vitro and cell based assays. ADR58 has an affinity of 7 nm for human OSM, and it can antagonize OSM binding to the gp130 receptor and specifically antagonize OSM mediated signaling. The aptamer has been truncated in length to 33 bases, all pyrimidine positions are substituted with 2' fluorine, and 14 of 18 purine positions have been substituted with 2' O-methyl to increase stability toward nucleases. This truncated, modified form of ADR58 retains complete affinity and functional activity for OSM. This aptamer may be used as a tool to further investigate the role of OSM in inflammatory disorders and may also have role as a therapeutic agent.
No takes yet. Share an insight, caveat, or question.
Rhodes et al. (2000) studied Inflammatory disorders / Rheumatoid arthritis. RNA aptamer ADR58 was evaluated on Affinity and functional activity for OSM. The RNA aptamer ADR58 binds human Oncostatin M with an affinity of 7 nm and specifically antagonizes its binding to the gp130 receptor and mediated signaling in vitro.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: